Pavlinec JG, Canales BK (2020) Improving care to decrease stone recurrence and opioid use. Nat Rev Urol 17:75–76

Article  CAS  PubMed  Google Scholar 

Ping H, Lu N, Wang M, Lu J, Liu Y, Qiao L, Wang Y, Jiang L, Zhang X (2019) New-onset metabolic risk factors and the incidence of kidney stones: a prospective cohort study. BJU Int 124:1028–1033

Article  PubMed  Google Scholar 

Lin G, Zhan F, Ren W, Pan Y, Wei W (2023) Association between novel anthropometric indices and prevalence of kidney stones in US adults. World J Urol 41:3105–3111

Article  PubMed  Google Scholar 

Torricelli FC, De SK, Gebreselassie S, Li I, Sarkissian C, Monga M (2014) Dyslipidemia and kidney stone risk. J Urol 191:667–672

Article  CAS  PubMed  Google Scholar 

Liu W, Wang M, Liu J, Yan Q, Liu M (2023) Causal effects of modifiable risk factors on kidney stones: a bidirectional mendelian randomization study. BMC Med Genomics 16:82

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hung JA, Li CH, Geng JH, Wu DW, Chen SC (2022) Dyslipidemia increases the risk of incident kidney Stone Disease in a large Taiwanese Population Follow-Up study. Nutrients 14

Wu Z, Liu L, Wang W, Cui H, Zhang Y, Xu J, Zhang W, Zheng T, Yang J (2022) Triglyceride-glucose index in the prediction of adverse cardiovascular events in patients with premature coronary artery disease: a retrospective cohort study. Cardiovasc Diabetol 21:142

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tian Y, Wu Y, Qi M, Song L, Chen B, Wang C, Lu J, Yang Y, Zhang X, Cui J et al (2024) Associations of remnant cholesterol with cardiovascular and cancer mortality in a nationwide cohort. Sci Bull (Beijing) 69:526–534

Article  CAS  PubMed  Google Scholar 

Li ZH, Hao QY, Zeng YH, Guo JB, Li SC, Gao JW, Yang PZ (2024) Remnant cholesterol and the risk of aortic valve calcium progression: insights from the MESA study. Cardiovasc Diabetol 23:20

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu X, Qiu W, He H, Zhao G, Liu J (2024) Associations of the triglyceride-glucose index and remnant cholesterol with coronary artery disease: a retrospective study. Lipids Health Dis 23:45

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yan Y, La R, Jiang M, Xu W, Jiang D, Wang S, Huang L, Wu Q (2024) The association between remnant cholesterol and rheumatoid arthritis: insights from a large population study. Lipids Health Dis 23:38

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang K, Wang R, Yang J, Liu X, Shen H, Sun Y, Zhou Y, Fang Z, Ge H (2022) Remnant cholesterol and atherosclerotic cardiovascular disease: metabolism, mechanism, evidence, and treatment. Front Cardiovasc Med 9:913869

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao M, Xiao M, Tan Q, Ji J, Lu F (2024) Cumulative residual cholesterol predicts the risk of cardiovascular disease in the general population aged 45 years and older. Lipids Health Dis 23:19

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yao L, Yang P (2024) Relationship between remnant cholesterol and risk of kidney stones in U.S. adults: a 2007–2016 NHANES analysis. Ann Med 56:2319749

Article  PubMed  PubMed Central  Google Scholar 

Stürzebecher PE, Katzmann JL, Laufs U (2023) What is ‘remnant cholesterol’? Eur Heart J 44:1446–1448

Article  PubMed  Google Scholar 

Blum MR, Tan YJ, Ioannidis JPA (2020) Use of E-values for addressing confounding in observational studies-an empirical assessment of the literature. Int J Epidemiol 49:1482–1494

Article  PubMed  Google Scholar 

Hong Y, Yu L, Huang X, An L, Xiong L, Xu Q, Xu T (2024) Composition analysis of renal and ureteral calculi in a single center in northern China in the past decade. Med (Baltim) 103:e37374

Article  CAS  Google Scholar 

Wu M, Chen W, Zhang S, Huang S, Zhang A, Zhang Y, Jia Z (2019) Rotenone protects against β-cell apoptosis and attenuates type 1 diabetes mellitus. Apoptosis 24:879–891

Article  CAS  PubMed  Google Scholar 

Zhang R, Bian C, Gao J, Ren H (2023) Endoplasmic reticulum stress in diabetic kidney disease: adaptation and apoptosis after three UPR pathways. Apoptosis 28:977–996

Article  PubMed  Google Scholar 

Khan SR, Canales BK, Dominguez-Gutierrez PR (2021) Randall’s plaque and calcium oxalate stone formation: role for immunity and inflammation. Nat Rev Nephrol 17:417–433

Article  CAS  PubMed  Google Scholar 

Ding Q, Ouyang J, Fan B, Cao C, Fan Z, Ding L, Li F, Tu W, Jin X, Wang J et al (2019) Association between Dyslipidemia and Nephrolithiasis Risk in a Chinese Population. Urol Int 103:156–165

Article  CAS  PubMed  Google Scholar 

Wang Z, Liu L, Li CY, Zhao YW, Tong XY, Cheng XY, Ouyang JM (2024) Carboxymethylated Rhizoma Alismatis polysaccharides reduces the risk of calcium oxalate stone formation by reducing cellular inflammation and oxidative stress. Urolithiasis 52:63

Article  PubMed  Google Scholar 

Brennan E, Kantharidis P, Cooper ME, Godson C (2021) Pro-resolving lipid mediators: regulators of inflammation, metabolism and kidney function. Nat Rev Nephrol 17:725–739

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chung J, Granja I, Taylor MG, Mpourmpakis G, Asplin JR, Rimer JD (2016) Molecular modifiers reveal a mechanism of pathological crystal growth inhibition. Nature 536:446–450

Article  CAS  PubMed  Google Scholar